One year ago when we published an in-depth review of the cell-based immunotherapy landscape, no one could have predicted the global COVID-19 pandemic and its associated disruptions. But researchers, drug developers, regulatory agencies, clinicians, and patients all worked hard to ensure that the cell therapy field continued to advance in oncology. In this paper, we will review some of those advancements and look ahead to 2021.
Specifically, we:
- Briefly align on the core design elements and open questions surrounding cell-based therapies in oncology.
- Review major research, regulatory, and commercial progress during 2020 that has addressed or begun to address these key questions.
- Outline the key milestones that we can expect for 2021-22.
